Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In Canada in 2020, the indication for use of Imvamune was expanded to include immunization against smallpox, mpox and related infection and disease in adults who are 18 years of age and older and determined to be at high risk for exposure.
Methods: Since the introduction of this new use for the vaccine and throughout the 2022 mpox outbreaks, the Public Health Agency of Canada (PHAC) has closely monitored the safety of the Imvamune vaccine through the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS).
Results: This article describes reports of adverse events following immunization (AEFI) after administration of Imvamune, submitted to the CAEFISS database between May 24, 2022 and December 11, 2022, during the activation of Canada's emergency response.
Conclusion: Monitoring of AEFI reports following immunization with Imvamune submitted to CAEFISS has not identified any new or unexpected safety concerns in the Canadian adult population. The Public Health Agency of Canada continues to monitor for potential vaccine safety signals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410834 | PMC |
| http://dx.doi.org/10.14745/ccdr.v51i08a05 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety monitoring of Imvamune vaccine during the 2022 mpox outbreak in Canada.
Can Commun Dis Rep
August 2025
Public Health Agency of Canada.
Background: In Canada in 2020, the indication for use of Imvamune was expanded to include immunization against smallpox, mpox and related infection and disease in adults who are 18 years of age and older and determined to be at high risk for exposure.
Methods: Since the introduction of this new use for the vaccine and throughout the 2022 mpox outbreaks, the Public Health Agency of Canada (PHAC) has closely monitored the safety of the Imvamune vaccine through the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS).
Results: This article describes reports of adverse events following immunization (AEFI) after administration of Imvamune, submitted to the CAEFISS database between May 24, 2022 and December 11, 2022, during the activation of Canada's emergency response.
Mpox (formerly-monkeypox) is the second viral pit break after COVID-19. It is a zoonotic viral illness caused by an belonging to the same genus as various cowpox and vaccinia viruses. The mpox virus has two clades, clade IIb, responsible for the disease's global expansion in 2022.
View Article and Find Full Text PDFMonkeypox: Prevention Strategies and Challenges: Updated Review.
Health Sci Rep
April 2025
Department of Midwifery School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University Addis Ababa Ethiopia.
Background And Aims: The mpox virus, sometimes known as MPXV, is the cause of the disease mpox. The Monkeypox virus is a different Poxviridae family member from the orthopoxvirus (OPXV) group. Clades I and II are the two varieties of the Monkeypox virus.
View Article and Find Full Text PDFSummary of the National Advisory Committee on Immunization (NACI) Statement-Updated guidance on Imvamune in the context of a routine immunization program.
Can Commun Dis Rep
January 2025
Department of Medicine, University of Alberta, Edmonton, AB.
Background: Mpox is a viral illness related to smallpox. It can cause flu-like symptoms and a rash, and in severe cases, can lead to hospitalization or death. The Imvamune® vaccine offers protection against mpox.
View Article and Find Full Text PDFA retrospective chart review and thematic analysis of patients seeking mpox vaccination during the initial outbreak in 2022-2023: evaluation of access, motivations, and stigma.
BMC Public Health
December 2024
School of Nursing, Health, York University, Rm. 329A, Health, Nursing and Environmental Studies Building, 104 Scholars Walk, Toronto, M3J 1P3, Canada.
Background: Mpox was identified in many previously non-endemic countries, including Canada, as of May 2022. In response to the increase in cases in Canada, and more specifically the province of Ontario, the vaccine Imvamune was rolled out. Eligibility was governed by provincial health authorities, and the response varied by region.
View Article and Find Full Text PDF